Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Leukemia
Published October 6, 2026
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethas...
October 7, 2026
Medspoke
Medspoke
Leukemia
Published October 6, 2026
00:00
--:--
Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced ...
October 7, 2026
Share
Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.
https://www.medspoke.co/channel_journal?id=683&tap_id=15198
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Leukemia
Published October 6, 2026
Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a ...
October 7, 2026
Why are you reporting this TALK?
